Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.

Use of other nicotine products common among vapers

05 Oct 2018
Vaping can help cut rates of smoking, says Reason Foundation think tank

Majority of users of electronic nicotine delivery systems (ENDS) also use other tobacco products, a recent study has shown.

Researchers surveyed a nationally representative sample of 3,517 adolescents and young adults, of whom only 281 (20.4 percent aged 13–17 years; 61.2 percent male) reported past 30-day ENDS use. Logistic regression analysis was employed to determine the probability of being an exclusive ENDS user.

More than half of the participants reported polytobacco use, (n=156; 17.2 percent aged 13–17 years), most of whom were male (65.5 percent). Only 44.1 percent (n=125; 24.3 percent aged 13–17 years; 55.9 percent male) used ENDS exclusively.

The most common tobacco product used with ENDS were cigarettes (11.5 percent) followed by cigars (7.7 percent), both cigars and water pipes (5.2 percent), water pipes alone (4.5 percent), and both cigarettes and cigars (4.0 percent).

Majority of the reported polytobacco involved only one (50.3 percent) or two (32.3 percent) other products; more than a tenth (13.4 percent) used three products with ENDS.

Multivariable adjusted analysis showed that risk perception was an important factor, such that those who viewed ENDS as less harmful than cigarettes were significantly more likely to be exclusive users than those who perceived ENDS to be as or more harmful than cigarettes (adjusted odds ratio, 2.6; 95 percent CI, 1.2–5.7).

No other factor, such as frequency of ENDS use, age, sex and socioeconomic status, was significantly predictive of polytobacco or exclusive patterns of use.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.